News

Gyros Protein Technologies introduces Gyrolab E. coli HCP Kit for automated impurity analysis of biotherapeutics

  • Ready-to-use immunoassay kit increases analytical output and productivity in bioprocess workflows
  • Kit developed as part of licensing and supply agreement with Cygnus Technologies

Uppsala, Sweden, 13 June 2019: Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today it has introduced a new host cell protein (HCP) kit for automated impurity analysis of biotherapeutics expressed in E. coli systems. The new kit is optimized for use in Gyrolab® systems and has been developed as part of a licensing and supply agreement with Cygnus Technologies (part of Maravai LifeSciences), incorporating their industry standard E. coli HCP antibodies and other reagents.

 

Gyrolab E. coli HCP Kit quantifies HCP impurities from E. coli expression systems used in the production of biotherapeutics, a critical step in ensuring the efficacy and safety of the drug molecule. As the latest addition to the growing menu of ready-to-use kits, the new kit is a key tool for the automated analysis of bioprocess samples, offering further support to customers working in biotherapeutics process development and manufacturing.

 

Gyros Protein Technologies has established expertise in bioprocess development, through its Gyrolab platforms and ready-to-use kits for CHO-HCP, Protein A impurity analyses, and IgG titer determinations. Gyrolab systems provide automated immunoassays for impurities such as HCPs, with a fast turn-around time, broad dynamic ranges and high reproducibility, making it an ideal technology to support all phases of biotherapeutic bioprocess development and production.

 

Jasmine Gruia-Gray, SVP Marketing, Gyros Protein Technologies, commented: “Gyrolab E. coli HCP Kit is a valuable addition to our growing portfolio of bioprocess kits, which help our customers to rapidly achieve critical analytical answers. This kit highlights our continued investment in expanded applications for the industry-leading Gyrolab systems, which are increasingly being adopted by customers to improve analytical output and workflow productivity.”

 

 

ENDS

Notes to editors

 

Gyrolab E. coli kit-webb

 

 

For a high resolution image please contact Zyme Communications

 

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.

 

Media contact:

Katie Odgaard

Zyme Communications

Tel: +44(0)7787 503 947

Email: Katie.odgaard@zymecommunications.com

 

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.

 

About Gyros Protein Technologies (For more information please click here)

Gyros Protein Technologies enables peptide synthesis and bioanalytical solutions that help scientists increase biomolecule performance and productivity in research, drug discovery, pre-clinical and clinical development, and bioprocess applications.  Our low to mid-scale peptide synthesizer platforms are the Tribute®, Prelude® X, Symphony® X, and Sonata®. These solutions and our chemistries deliver uncompromising purity, flexibility, and quality for discovery and pre-clinical studies of simple to complex multifunctional peptides. Proprietary high performance nanoliter-scale immunoassay platforms, Gyrolab® xPand, Gyrolab xP workstation and Gyrolab xPlore™, are used by scientists in leading pharmaceutical, biotech, CRO, and CMO companies for bioanalytical applications such as pharmacokinetics/pharmacodynamics, immunogenicity, and quantitating bioprocess-related impurities. Our peptide synthesis and bioanalytical solutions accelerate your discovery, development, and manufacturing of safer biotherapeutics.

Topics: Gyros, news on home